Clinical Safety. Regulatory Transparency. Structured Oversight.
Patient safety is addressed through documented sourcing practices, standardized processing procedures, and regulatory registration where applicable. Oversight considerations extend throughout material handling, laboratory processing, and clinical use.
Safety protocols begin prior to clinical application. Regenerative biologic materials are processed in U.S.-based laboratories that are registered with the FDA as required by federal regulations. Registration does not constitute FDA approval of a specific therapy or outcome. Laboratories operate in accordance with applicable regulatory standards, including Current Good Tissue Practices (CGTPs), which outline requirements for processing, handling, and documentation.
From donor screening (when applicable) through laboratory processing and final release procedures, steps are taken to support traceability, sterility controls, and quality documentation. Patients are encouraged to review available regulatory and laboratory information as part of informed decision-making.
Independent Third-Party Testing
All safety testing is conducted through independent FDA/CLIA-certified laboratories and includes multiple layers of verification. This process begins with comprehensive donor communicable disease screening, followed by tissue and final product validation. Sterility testing is performed to confirm the absence of contamination, and endotoxin testing is completed prior to final preparation to verify that the product meets strict safety standards.
Appendix C: Donor Communicable Disease Testing (Page 15) Appendix D: Endotoxin Testing (Page 16)
Final product meets sterility standards of <0.005 EU/mL.
Conditions Often Treated with Regenerative Care
- Consultation & medical history review
- Imaging review (X-ray, MRI if applicable)
- Personalized treatment plan discussion
Regenerative Consultation
Why Consult With Us?
Book an Appointment
Safety & Clinical Oversight FAQs
Regenerative therapy is provided within a structured clinical setting that emphasizes patient evaluation, informed consent, and procedural standards. Before treatment is considered, a comprehensive review of medical history, current health status, and individual goals is performed.
As with any medical procedure, risks may exist and vary by individual. A detailed discussion of potential risks, benefits, and alternatives should occur prior to treatment.
Regenerative therapy is delivered under qualified medical supervision. Treatment planning is based on clinical assessment, professional judgment, and patient-specific factors.
Ongoing monitoring may be recommended depending on the individual treatment plan. Oversight does not eliminate risk, but it supports responsible clinical decision-making.
Regenerative therapies fall within a developing area of medicine. Certain components or materials used in treatment may be regulated, while broader regenerative approaches may not be FDA-approved for specific conditions.
Patients should discuss regulatory status, intended use, and limitations with their healthcare provider to make informed decisions.
Potential risks vary depending on the specific procedure and individual health factors. As with many minimally invasive procedures, possible risks may include discomfort, swelling, bruising, infection, or other complications.
Individual responses differ, and outcomes are not guaranteed. A consultation is essential to understand how potential risks may apply in your situation.
Regenerative therapy is often performed in an outpatient setting and may be considered by some individuals exploring non-surgical options. However, it is not appropriate for everyone, and it should not be described as risk-free.
Each patient’s condition, health status, and treatment goals determine whether a regenerative approach may be suitable.
Candidacy is determined through individualized evaluation. This typically includes medical history review, physical assessment, and discussion of goals and expectations.
Not all individuals are appropriate candidates. A qualified provider will determine whether regenerative therapy may align with your clinical profile.
No. Individual responses to regenerative therapy vary based on numerous factors, including overall health, condition severity, and adherence to care recommendations.
These services are designed to support aspects of the body’s natural processes, but specific outcomes cannot be predicted or guaranteed.
Prior to treatment, patients should receive clear information regarding:
The nature of the procedure
Potential risks and limitations
Alternative treatment options
The absence of guaranteed outcomes
Informed consent supports patient understanding and shared decision-making.